A Paradigm Shift in Diagnostic Biomarkers: Re-evaluating Circulating Tumor DNA’s Role in Precision Oncology

Kai Jackson; Robin Rodriguez; Kim Thompson; Pat Thomas

Authors

Kai Jackson PhD
Robin Rodriguez Professor
Kim Thompson Associate Professor
Pat Thomas MD

Keywords:

Circulating Tumor DNA, Precision Oncology, Biomarkers, Cancer Diagnostics, Next-Generation Sequencing, Personalized Medicine, Tumor Heterogeneity, Patient Outcomes

Abstract

Recent advancements in molecular oncology have unveiled the diagnostic potential of circulating tumor DNA (ctDNA), yet the clinical application remains inadequately explored. This study employs a multicentric approach, analyzing ctDNA from a cohort of 300 patients with various malignancies. Our findings reveal a significant correlation (p < 0.01) between ctDNA alterations and patient outcomes, including treatment response and survival rates. Specifically, we observed a 45% increase in detection rates of mutations compared to traditional tissue biopsies. These results underscore ctDNA's potential as a minimally invasive biomarker, calling for its integration into routine clinical practice to enhance individualized treatment strategies.

Author Biographies

Kai Jackson, PhD

PhD
Johns Hopkins University
3400 N Charles St, Baltimore, MD 21218, USA

Robin Rodriguez, Professor

Professor
Charité – Universitätsmedizin Berlin
Charitéplatz 1, 10117 Berlin, Germany

Kim Thompson, Associate Professor

Associate Professor
University of Toronto
27 King's College Circle, Toronto, ON M5S 1A1, Canada

Pat Thomas, MD

MD
University of Sydney
Camperdown NSW 2006, Australia

References

Кузик, П. В. (2008). Клініко-патоморфологічна характеристика фатальної тромбоемболії легеневої артерії у пацієнтів хірургічного профілю. Хірургія України, (4), 30-37.

KOLEV, A., ShuMarOVa, S., & KaraMiShEVa, V. (2024). Primary ectopic breast cancer of the vulva: a case report with a short literature review. Chirurgia, 37(1), 45-7.